Combined Survivin inhibitor and mTOR inhibitor Induce Necroptosis on Renal Cell Carcinoma: Mechanisms and Effects
博士 === 國立清華大學 === 分子與細胞生物研究所 === 101 === Renal cell carcinoma (RCC) is one of the most lethal urinary malignancies and causes about 13,570 estimated cancer-related deaths in the United States in 2012 . RCC accounts for about 500 new cancer cases per year in Taiwan. New targeted therapy focusing on...
Main Authors: | Chao, Cheng-Han, 趙政漢 |
---|---|
Other Authors: | Lin, Lih-Yuan |
Format: | Others |
Language: | zh-TW |
Published: |
2013
|
Online Access: | http://ndltd.ncl.edu.tw/handle/98808685095054343907 |
Similar Items
-
Combination of mTOR and MAPK Inhibitors—A Potential Way to Treat Renal Cell Carcinoma
by: Ashutosh Chauhan, et al.
Published: (2016-10-01) -
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
by: Sumanta Kumar Pal, et al.
Published: (2010-01-01) -
mTOR signaling pathway and mTOR inhibitors in the treatment of cancer
by: Mehmet Küçüköner, et al.
Published: (2013-03-01) -
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01) -
A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.
by: Shujie Yang, et al.
Published: (2011-01-01)